Trastuzumab Deruxtecan Beats Standard Even in Very Low HER2 Metastatic Breast Cancer

Already approved for HER2-low metastatic breast cancer (MBC) after at least one line of chemotherapy, the ...

AUGUST 7, 2024

Enhertu Approved for Unresectable or Metastatic HER2-positive Solid Tumors

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult ...

APRIL 8, 2024

Patients With HER2-Low Early Breast Cancer Respond to Trastuzumab Deruxtecan

Neoadjuvant trastuzumab deruxtecan (T-DXd) (Enhertu, Daiichi Sankyo) produced responses and decreased HER2 ...

DECEMBER 28, 2022

Enhertu Approved as HER2-Directed Therapy for Certain Lung Cancer Patients

The FDA granted a new indication for trastuzumab deruxtecan-nxki (Enhertu, AstraZeneca/Daiichi Sankyo) to treat ...

AUGUST 12, 2022

FDA Approves First Targeted Therapy for HER2-Low Breast Cancer

The FDA approved fam-trastuzumab-deruxtecan-nxki, (Enhertu, Daiichi-Sankyo/AstraZeneca) for the treatment of ...

AUGUST 8, 2022

FDA Approves Enhertu to Treat Gastric and GEJ Adenocarcinomas

The FDA approved approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo/AstraZeneca) for adults with ...

JANUARY 29, 2021

Enhertu: New Option for Previously Treated Unresectable or Metastatic HER2+ Breast Ca

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for the treatment ...

JANUARY 7, 2020